Unique oral peptide delivery technology
Superior oral bioavailability compared to state-of-the-art peptide tablet technologies
Strong expertise and experience in oral delivery of macrocyclic peptides and GLP-1 peptides
Oral delivery of PROTACs and other Biopharmaceutics Classification System injectable (BCS Class IV) drugs

CYPRUMED | Oral Peptide Delivery Experts

Drug delivery technologies for the non-invasive administration of biologics.

We are collaborating with various pharma partners, including Bayer, Boehringer Ingelheim and Ferring and have entered a license and option agreement with MSD.

10+ years of experience

Unique technology

Collaborations with leading pharma companies

Patent protection and FTO

Latest news

January, 2026

Cyprumed announces the appointment of Martin E. Judge as Chief Business Officer, effective immediately.

With deep experience in pharma/biotech licensing, strategy and establishment of partnerships, Martin will play a key role in advancing our mission and executing our strategy. He has a background in life sciences and technologies in areas relevant to the Pharma industry based on his education (PhD in Basic Medical Sciences, New York University) and professional experience in R&D and Business Development at Novo Nordisk.

Welcome to the team!

September – October, 2025

Cyprumed signs feasibility agreements with two additional top 20 pharma companies

September, 2025

Cyprumed publishes original research article on oral peptide delivery in Journal of Controlled Release.

Read more

More news

Areas of expertise

Cyprumed specializes in innovative oral delivery solutions for peptides such as GLP-1 agonists and Biopharmaceutics Classification System injectable (BCS Class IV) drugs, offering superior tablet formulations for enhanced bioavailability. With its team of experts and network, and its proprietary delivery platform, Cyprumed is at the forefront of the oral drug delivery technology industry. Cyprumed enables the transformation of novel peptides and BCS IV compounds into high-quality oral drug products.

Learn more
Close-up of someone pouring a variety of pills from a prescription bottle into their hand

Cyprumed technology

The Cyprumed technology offers advantages over current delivery systems. We offer three oral drug delivery platforms: intestinal and gastric peptide delivery, and oral delivery of Biopharmaceutics Classification System injectable (BCS Class IV) drugs. By selecting the right delivery platform for your compound, we can make your API orally bioavailable.

Learn more
„Our technology is not only highly efficient, but also easy to produce and scale-up, while fulfilling key regulatory requirements.“
Florian Föger, PhD, CEO
Want to collaborate?

Are you interested in a possible collaboration? Do you have any questions? We look forward to hearing from you!

Message us